IgG4-related disease: a condition with a short history and wide reach
IgG4-related disease (IgG4-RD) was only formally recognised as a unified disease entity in the early 2000s. Before this consolidation, its organ-specific manifestations had accumulated separate names across specialties: autoimmune pancreatitis type 1 in gastroenterology; IgG4-associated cholangitis or sclerosing cholangitis in hepatology; Mikulicz disease (symmetric swelling of lacrimal and salivary glands) in rheumatology and ophthalmology; Riedel’s thyroiditis in endocrinology; orbital inflammatory pseudotumour in ophthalmology; retroperitoneal fibrosis and periaortitis in vascular surgery. The recognition that these apparently disparate conditions share identical histopathological features, elevated serum IgG4 in many cases, and responsiveness to corticosteroids transformed understanding across multiple specialties and established IgG4-RD as a systemic disease category.
The seminal work establishing the unified concept came from Hamano and colleagues in Japan (2001), who identified elevated serum IgG4 in autoimmune pancreatitis, and from Stone, Deshpande, and collaborators at Massachusetts General Hospital who comprehensively characterised the histopathological and clinical features that define IgG4-RD across organs. The 2012 consensus statement in the Arthritis & Rheumatism journal established diagnostic criteria that integrated pathology, serology, and imaging.
The pathological triad: plasma cells, fibrosis, and phlebitis
The histopathological diagnosis of IgG4-RD rests on three features that, when present together in adequate biopsy material, are diagnostic. First, a dense lymphoplasmacytic infiltrate, specifically enriched for IgG4-positive plasma cells (IgG4+ cells constituting more than 40% of all IgG-positive plasma cells, with an IgG4:IgG ratio exceeding 40%). Second, storiform fibrosis — a distinctive “cartwheel” or “storiform” pattern in which collagen bundles radiate from cellular foci, creating a swirling appearance on low-power histology that differs from the parallel or haphazard fibrosis of other conditions. Third, obliterative phlebitis — inflammation of veins leading to luminal occlusion by fibrotic tissue. This vascular involvement explains why IgG4-RD lesions often appear as mass-like lesions on imaging: the fibrotic and inflammatory process distorts normal architecture and can mimic malignancy, leading to inappropriate surgical resection before the diagnosis is recognised.
Serum IgG4 elevation (conventionally defined as greater than 135 mg/dL) is present in approximately 60–70% of IgG4-RD patients at diagnosis and correlates with disease activity, making it a useful monitoring biomarker. However, elevated serum IgG4 is not specific for IgG4-RD — it is also seen in atopic disease, parasitic infections, pemphigus, and some solid organ malignancies — and normal serum IgG4 does not exclude IgG4-RD. The diagnostic weight rests primarily on histopathology, with serology as a supporting rather than defining criterion.
The unusual biochemistry of IgG4
IgG4 is the rarest IgG subclass, constituting less than 5% of total IgG in healthy individuals, and has several biochemically distinctive properties that bear on why IgG4-RD is, paradoxically, a fibro-inflammatory disease driven by an antibody subclass generally associated with regulatory immune responses.
IgG4 undergoes a phenomenon called Fab arm exchange: the two heavy chains of an IgG4 molecule are held together by weak non-covalent interactions in the hinge region rather than disulfide bonds, allowing IgG4 molecules to exchange half-antibodies (one heavy chain plus its paired light chain) with other IgG4 molecules in circulation. The result is that most circulating IgG4 is functionally bispecific but monovalent for any individual antigen — it can bind two different antigens simultaneously but cannot crosslink two copies of the same antigen. This structural feature prevents IgG4 from forming the immune complexes that activate complement and FcγR-bearing effector cells, which is why elevated serum IgG4 does not produce the classical immune complex nephritis or vasculitis seen with IgG1 or IgG3 accumulation.
IgG4 also has reduced affinity for FcRn at acidic pH (relevant to its half-life) and poor complement activation capacity (C1q binding is greatly diminished compared to IgG1). The immunological interpretation of high-level IgG4 production has traditionally been as a regulatory or “blocking” antibody response — as seen in beekeepers who develop tolerance to venom despite high venom-specific IgG4, or in allergen immunotherapy where therapeutic benefit correlates with IgG4 induction. The paradox of IgG4-RD is that the same antibody subclass considered a marker of tolerance is, in this disease, associated with tissue destruction — suggesting that it is not the IgG4 itself that is primarily pathogenic but rather the CD4+ T cells and other effectors that drive the fibrotic process.
Pathogenesis: the Th2/Treg/Tfh13 triad
The cellular pathogenesis of IgG4-RD has been substantially clarified over the past decade. The current model involves three CD4+ T cell populations acting in concert to drive the characteristic fibrotic, IgG4-switching response.
Conventional Th2 cells producing IL-4 and IL-13 drive IgG4 class switching through IL-4’s direct effect on B cell isotype switching — IL-4 signalling through IL-4Rα/IL-2Rγc complex on B cells activates JAK1/3-STAT6 and switches immunoglobulin constant region usage from IgM to IgG4 (and IgE). IL-13 has complementary effects on fibrosis, activating TGF-β production and directly stimulating fibroblast collagen deposition.
A recently characterised subset, termed Tfh13 (follicular helper T cells producing IL-13), has been identified by Maehara and colleagues as particularly prominent in IgG4-RD germinal centres. Tfh13 cells drive both the B cell IgG4 class switch and IL-13-mediated fibrosis, linking antibody production to the tissue-destructive fibrotic process in a single cell population. Tfh13 cells are also important in allergic disease, suggesting that IgG4-RD shares cellular pathogenesis with the atopic spectrum — consistent with the clinical observation that many IgG4-RD patients have personal or family histories of atopy.
Regulatory T cells producing TGF-β contribute independently to fibrosis. TGF-β signalling through Smad2/3 in fibroblasts drives myofibroblast differentiation (alpha-smooth muscle actin upregulation) and collagen I/III deposition. The storiform fibrosis characteristic of IgG4-RD reflects this TGF-β-driven fibroblast activation occurring in an anatomically disorganised manner around infiltrating lymphoplasmacytic cells. Tregs also suppress cytotoxic immune responses, which may contribute to the persistence of the offending antigen — potentially microbial, self, or environmental — that drives the sustained adaptive immune response.
A “two-hit” model has been proposed: an initial innate immune activation (perhaps microbial, traumatic, or autoimmune) provides the first hit, activating dendritic cells and establishing an inflammatory tissue environment; the second hit is the adaptive Th2/Tfh13 response that drives the IgG4 class switch and fibrotic programme. This model is supported by the finding that innate immune gene expression signatures (NLRP3, IL-1β) are elevated in affected tissues alongside the adaptive Th2 signature.
Treatment: glucocorticoids and rituximab
IgG4-RD responds dramatically to glucocorticoids in most patients — often within days of initiating treatment, with radiological evidence of mass lesion resolution within weeks. Prednisolone 30–40 mg/day (0.5–0.6 mg/kg/day) is standard for remission induction, with a tapering schedule over several months. Relapse rates after glucocorticoid withdrawal are high (40–60% at one year in some series), particularly in patients with lacrimal gland involvement, proximal bile duct involvement, or who are IgG4-subclass-high at diagnosis.
Rituximab (anti-CD20 monoclonal antibody, depleting B cells) is effective for refractory or relapsing IgG4-RD. The mechanism is depletion of the plasmablast and memory B cell populations that produce IgG4 and provide cognate T cell help. Serum IgG4 falls rapidly after rituximab infusion, and clinical and radiological responses are achieved in most patients. Given the Th2/Tfh13 pathogenesis, biologic strategies targeting IL-4/IL-13 signalling (dupilumab, tralokinumab) are under investigation and have shown promise in case series and small trials.
Where spirulina’s immunomodulatory profile is relevant — and where it is not
Spirulina’s documented immunomodulatory effects include Th1 stimulation through NK cell activation and IFN-γ induction, and Th2 dampening through reduction of IL-4 and IL-13 production in allergic cell models. Phycocyanin has been shown in multiple in vitro and murine allergic model studies to reduce IL-4 and IL-13 production from sensitised mast cells and Th2-polarised T cells. These effects are biologically relevant to IgG4-RD pathogenesis because IL-4 is the primary driver of IgG4 class switching and IL-13 drives the fibrotic programme.
A theoretical case can be constructed: if spirulina’s phycocyanin reduces IL-4/IL-13 production in vivo at the relevant tissue level, it could partially dampen the Th2-mediated IgG4 class switch and the IL-13-driven fibroblast activation. This mechanism would be analogous to, though far weaker than, dupilumab’s complete IL-4Rα blockade.
The complexity, and the reason this analysis must be honest rather than promotional, is the “two-hit” model. Spirulina is a Th1/NK cell activator — it upregulates natural killer cell cytotoxicity, IFN-γ, and innate immune activation. If the first hit in IgG4-RD pathogenesis is innate immune activation, then a supplement that stimulates NK cells and innate immune responses could theoretically worsen or trigger the initial inflammatory event that sets the pathogenic cascade in motion. This is speculative — there is no evidence that spirulina consumption causes or exacerbates IgG4-RD — but it is an honest acknowledgment that the immunological effects of spirulina are bidirectional in ways that make simple recommendations in autoimmune contexts problematic.
The coexistence of Th1-activating and Th2-dampening effects in spirulina reflects its complex biochemistry. The net immune effect in a given individual depends on baseline immune state, dose, duration, and the specific tissue context. In healthy individuals or in Th2-skewed conditions like allergy, the Th2-dampening effects may predominate. In a condition like IgG4-RD where innate immune overactivation may be an early pathogenic event, even a modest Th1/innate amplification could be unfavourable.
The NF-κB connection and fibrosis
Phycocyanin’s well-documented suppression of NF-κB activity is relevant to the fibrotic process in IgG4-RD. NF-κB drives transcription of pro-inflammatory cytokines that sustain fibroblast activation, and its suppression in fibroblasts has been shown to reduce myofibroblast differentiation in multiple fibrotic disease models. Additionally, NF-κB is required for NLRP3 inflammasome priming — the first signal for NLRP3 activation that induces pro-IL-1β expression — suggesting that phycocyanin’s NF-κB suppression could reduce the innate inflammatory driver in IgG4-RD.
Here the “two-hit” model actually provides grounds for cautious optimism: if spirulina reduces NF-κB-dependent innate immune activation (the first hit) through phycocyanin while simultaneously dampening IL-4/IL-13 (the second hit), its net effect might be anti-pathogenic in IgG4-RD. But this reasoning requires a mechanistic consistency across the two “hits” that may not hold in practice — the innate immune activation in IgG4-RD is NF-κB-dependent, while the NK cell activation by phycocyanin appears to be independent of, or upstream of, NF-κB.
Conclusion: theoretical interest, significant uncertainty
IgG4-related disease is a Th2/Treg-driven fibro-inflammatory condition whose pathogenesis implicates the IL-4/IL-13 cytokine axis, TGF-β-driven fibrosis, and innate immune priming — all pathways where phycocyanin and spirulina have documented activities in non-IgG4-RD experimental contexts. The theoretical mechanistic case for spirulina’s relevance is genuine and not forced.
However, no clinical or even rigorous preclinical data exists on spirulina in IgG4-RD specifically. The condition is uncommon (population prevalence estimates range from 6–10 per 100,000 in Japanese cohorts), the diagnosis is histopathological and requires specialist input, and the established treatments — corticosteroids and rituximab — are highly effective when used appropriately. Anyone with a confirmed or suspected IgG4-RD diagnosis should be managed by specialists, not by dietary intervention. Spirulina’s potential relevance here is as a research-worthy mechanistic connection, not as a clinical recommendation.